GloFish, the first genetically modified animal to be sold as a pet
A genetically modified organism (GMO) is an organism whose genetic material has been altered using genetic engineering techniques. Organisms that have been genetically modified include micro-organisms such as bacteria and yeast, insects, plants, fish, and mammals. GMOs are the source of genetically modified foods, and are also widely used in scientific research and to produce goods other than food. The term GMO is very close to the technical legal term, 'living modified organism' defined in the Cartagena Protocol on Biosafety, which regulates international trade in living GMOs (specifically, "any living organism that possesses a novel combination of genetic material obtained through the use of modern biotechnology").
Genetic modification involves the mutation, insertion, or deletion of genes. When genes are inserted, they usually come from a different species, which is a form of horizontal gene transfer. In nature this can occur when exogenous DNA penetrates the cell membrane for any reason. To do this artificially may require attaching the genes to a virus or just physically inserting the extra DNA into the nucleus of the intended host with a very small syringe, with the use of electroporation using electricity to permeate the cell membrane for transfection or with very small particles fired from a gene gun. However, other methods exploit natural forms of gene transfer, such as the ability of Agrobacterium to transfer genetic material to plants, or the ability of lentiviruses to transfer genes to animal cells.
The general principle of producing a GMO is to alter the genetic material of an organism's genome. This may involve mutating, deleting, or adding genetic material. When genetic material from a different species is added, the resulting DNA is called recombinant DNA and the organism is called a transgenic organism. The first recombinant DNA molecules were produced by Paul Berg in 1972.
GMOs are used in biological and medical research, production of pharmaceutical drugs, experimental medicine (e.g. gene therapy), and agriculture (e.g. golden rice, resistance to herbicides). The term "genetically modified organism" does not always imply, but can include, targeted insertions of genes from one species into another. For example, a gene from a jellyfish, encoding a fluorescent protein called GFP, can be physically linked and thus co-expressed with mammalian genes to identify the location of the protein encoded by the GFP-tagged gene in the mammalian cell. Such methods are useful tools for biologists in many areas of research, including those who study the mechanisms of human and other diseases or fundamental biological processes in eukaryotic or prokaryotic cells.
Transgenic plants have been engineered for scientific research, to create new colours in plants, and to create different crops.
In research, plants are engineered to help discover the functions of certain genes. One way to do this is to knock out the gene of interest and see what phenotype develops. Another strategy is to attach the gene to a strong promoter and see what happens when it is over expressed. A common technique used to find out where the gene is expressed is to attach it to GUS or a similar reporter gene that allows visualisation of the location.'
Suntory "blue" rose
After thirteen years of collaborative research, an Australian company – Florigene, and a Japanese company – Suntory, created a blue rose (actually lavender or mauve) in 2004. The genetic engineering involved three alterations – adding two genes, and interfering with another. One of the added genes was for the blue plant pigmentdelphinidin cloned from the pansy. The researchers then used RNA interference (RNAi) technology to depress all color production by endogenous genes by blocking a crucial protein in color production, called dihydroflavonol 4-reductase) (DFR), and adding a variant of that protein that would not be blocked by the RNAi but that would allow the delphinidin to work. The roses are sold worldwide. Florigene has also created and sells lavender-colored carnations that are genetically engineered in a similar way.
In agriculture, currently marketed genetically engineered crops have traits such as resistance to pests, resistance to herbicides, increased nutritional value, or production of valuable goods such as drugs (pharming); products under development include crops able to thrive in environmental conditions outside the species' native range or in changed conditions in their range (e.g. drought or salt resistance); products that existed and have been withdrawn include those with extended product shelf life such as the Flavr-savr tomato. Since the first commercial cultivation of genetically modified plants in 1996, they have been modified to be tolerant to the herbicides glufosinate and glyphosate, to be resistant to virus damage as in Ringspot virus-resistant GM papaya, grown in Hawaii, and to produce the Bt toxin, an insecticide that is documented as non-toxic to mammals.
Second and third generation GM crops are on the market and under development with improved nutrition profiles and increased yields or ability to thrive in difficult environments. GM oilseed crops on the market today offer improved oil profiles for processing or healthier edible oils. Other examples include: a genetically modified cassava with lower cyanogen glucosides and enhanced with protein and other nutrients;golden rice, developed by the International Rice Research Institute (IRRI), has been discussed as a possible cure for Vitamin A deficiency; a vitamin-enriched corn derived from South African white corn variety;camelina sativa that accumulates high levels of oils similar to fish oils.
Cisgenesis, sometimes also called intragenesis, is a product designation for a category of genetically engineered plants. A variety of classification schemes have been proposed that order genetically modified organisms based on the nature of introduced genotypical changes rather than the process of genetic engineering.
While some genetically modified plants are developed by the introduction of a gene originating from distant, sexually incompatible species into the host genome, cisgenic plants contain genes that have been isolated either directly from the host species or from sexually compatible species. The new genes are introduced using recombinant DNA methods and gene transfer. Some scientists hope that the approval process of cisgenic plants might be simpler than that of proper transgenics, but it remains to be seen.
Bacteria were the first organisms to be modified in the laboratory, due to their simple genetics. These organisms are now used for several purposes, and are particularly important in producing large amounts of pure human proteins for use in medicine.
In addition, various genetically engineered micro-organisms are routinely used as sources of enzymes for the manufacture of a variety of processed foods. These include alpha-amylase from bacteria, which converts starch to simple sugars, chymosin from bacteria or fungi that clots milk protein for cheese making, and pectinesterase from fungi which improves fruit juice clarity.
Some chimeras, like the blotched mouse shown, are created through genetic modification techniques like gene targeting.
Genetically modified mammals are an important category of genetically modified organisms.Ralph L. Brinster and Richard Palmiter developed the techniques responsible for transgenic mice, rats, rabbits, sheep, and pigs in the early 1980s, and established many of the first transgenic models of human disease, including the first carcinoma caused by a transgene. The process of genetically engineering animals is a slow, tedious, and expensive process. However, new technologies are making genetic modifications easier and more precise.
The first transgenic (genetically modified) animal was produced by injecting DNA into mouse embryos then implanting the embryos in female mice.
Genetically modified animals currently being developed can be placed into six different broad classes based on the intended purpose of the genetic modification:
to research human diseases (for example, to develop animal models for these diseases);
to produce industrial or consumer products (fibres for multiple uses);
to produce products intended for human therapeutic use (pharmaceutical products or tissue for implantation);
to enrich or enhance the animals' interactions with humans (hypo-allergenic pets);
to enhance production or food quality traits (faster growing fish, pigs that digest food more efficiently);
Transgenic animals are used as experimental models to perform phenotypic and for testing in biomedical research.
Genetically modified (genetically engineered) animals are becoming more vital to the discovery and development of cures and treatments for many serious diseases. By altering the DNA or transferring DNA to an animal, we can develop certain proteins that may be used in medical treatment. Stable expressions of human proteins have been developed in many animals, including sheep, pigs, and rats. Human-alpha-1-antitrypsin, which has been tested in sheep and is used in treating humans with this deficiency and transgenic pigs with human-histo-compatibility have been studied in the hopes that the organs will be suitable for transplant with less chances of rejection.
Enviropig was a genetically enhanced line of Yorkshire pigs in Canada created with the capability of digesting plant phosphorus more efficiently than conventional Yorkshire pigs. The project ended in 2012. These pigs produced the enzyme phytase, which breaks down the indigestible phosphorus, in their saliva. The enzyme was introduced into the pig chromosome by pronuclear microinjection. With this enzyme, the animal is able to digest cereal grain phosphorus. The use of these pigs would reduce the potential of water pollution since they excrete from 30 to 70.7% less phosphorus in manure depending upon the age and diet. The lower concentrations of phosphorus in surface runoff reduces algal growth, because phosphorus is the limiting nutrient for algae. Because algae consume large amounts of oxygen, it can result in dead zones for fish.
In 2011, Chinese scientists generated dairy cows genetically engineered with genes for human beings to produce milk that would be the same as human breast milk. This could potentially benefit mothers who cannot produce breast milk but want their children to have breast milk rather than formula. Aside from milk production, the researchers claim these transgenic cows to be identical to regular cows. Two months later scientists from Argentina presented Rosita, a transgenic cow incorporating two human genes, to produce milk with similar properties as human breast milk. In 2012, researchers from New Zealand also developed a genetically engineered cow that produced allergy-free milk.
Goats have been genetically engineered to produce milk with strong spiderweb-like silk proteins in their milk.
Genetically modified fish have been developed with promoters driving an over-production of growth hormone for use in the aquaculture industry to increase the speed of development and potentially reduce fishing pressure on wild stocks. AquaBounty, a biotechnology company working on bringing a GM salmon to market, claims that their GM AquAdvantage salmon can mature in half the time it takes non-GM salmon and achieves twice the size. AquaBounty has applied for regulatory approval to market their GM salmon in the US. As of May 2012 the application was still pending.On 25 November 2013 Canada approved commercial scale production and export of GM Salmon eggs but they are not approved for human consumption in Canada.
In biological research, transgenic fruit flies (Drosophila melanogaster) are model organisms used to study the effects of genetic changes on development. Fruit flies are often preferred over other animals due to their short life cycle, low maintenance requirements, and relatively simple genome compared to many vertebrates.
In 2010, scientists created "malaria-resistant mosquitoes" in the laboratory. The World Health Organization estimated that Malaria killed almost one million people in 2008. Genetically modified male mosquitoes containing a lethal gene have been developed in order to combat the spread of Dengue fever.Aedes aegypti mosquitoes, the single most important carrier of dengue fever, were reduced by 80% in a 2010 trial of these GM mosquitoes in the Cayman Islands. Between 50 and 100 million people are affected by Dengue fever every year and 40,000 people die from it.
A strain of Pectinophora gossypiella (Pink bollworm) has been developed that contains a fluorescent marker in their DNA. This allows researchers to monitor bollworms that have been sterilized by radiation and released in order to reduce bollworm infestation.
Cnidarians such as Hydra and the sea anemone Nematostella vectensis have become attractive model organisms to study the evolution of immunity and certain developmental processes. An important technical breakthrough was the development of procedures for generation of stably transgenic hydras and sea anemones by embryo microinjection.
GM fish are used for scientific research and as pets, and are being considered for use as food and as aquatic pollution sensors.
Genetically engineered fish are widely used in basic research in genetics and development. Two species of fish, zebrafish and medaka, are most commonly modified because they have optically clear chorions (shells), rapidly develop, and the 1-cell embryo is easy to see and microinject with transgenic DNA.
The GloFish is a patented brand of genetically modified (GM) fluorescent zebrafish with bright red, green, and orange fluorescent color. Although not originally developed for the ornamental fish trade, it became the first genetically modified animal to become publicly available as a pet when it was introduced for sale in 2003. They were quickly banned for sale in California.
Genetically modified fish have been developed with promoters driving an over-production of "all fish" growth hormone for use in the aquaculture industry to increase the speed of development and potentially reduce fishing pressure on wild stocks. This has resulted in dramatic growth enhancement in several species, including salmon,trout and tilapia. AquaBounty, a biotechnology company working on bringing a GM salmon to market, claims that their GM AquAdvantage salmon can mature in half the time it takes non-GM salmon and achieves twice the size. AquaBounty has applied for regulatory approval to market their GM salmon in the US. As of December 2012 the application was still pending.
Several academic groups have been developing GM zebrafish to detect aquatic pollution. The lab that originated the GloFish discussed above originally developed them to change color in the presence of pollutants, to be used as environmental sensors. A lab at University of Cincinnati has been developing GM zebrafish for the same purpose, as has a lab at Tulane University.
The regulation of genetic engineering concerns the approaches taken by governments to assess and manage the risks associated with the use of genetic engineering technology and the development and release of genetically modified organisms (GMO), including genetically modified crops and genetically modified fish. There are differences in the regulation of GMOs between countries, with some of the most marked differences occurring between the USA and Europe. Regulation varies in a given country depending on the intended use of the products of the genetic engineering. For example, a crop not intended for food use is generally not reviewed by authorities responsible for food safety. The European Union differentiates between approval for cultivation within the EU and approval for import and processing. While only a few GMOs have been approved for cultivation in the EU a number of GMOs have been approved for import and processing.  The cultivation of GMOs has triggered a debate about coexistence of GM and nonGM crops. Depending on the coexistence regulations incentives for cultivation of GM crops differ.
There is controversy over GMOs, especially with regard to their use in producing food. The dispute involves consumers, biotechnology companies, governmental regulators, non-governmental organizations, and scientists. The key areas of controversy related to GMO food are whether GM food should be labeled, the role of government regulators, the effect of GM crops on health and the environment, the effect on pesticide resistance, the impact of GM crops for farmers, and the role of GM crops in feeding the world population.
There is broad scientific consensus that food on the market derived from GM crops poses no greater risk than conventional food. No reports of ill effects have been documented in the human population from GM food. Although labeling of GMO products in the marketplace is required in many countries, it is not required in the United States and no distinction between marketed GMO and non-GMO foods is recognized by the US FDA.
Advocacy groups such as Greenpeace, The Non-GMO Project and Organic Consumers Association say that risks of GM food have not been adequately identified and managed, and have questioned the objectivity of regulatory authorities. Opponents say that food derived from GMOs may be unsafe and propose it be banned, or at least labeled. They have expressed concerns about the objectivity of regulators and rigor of the regulatory process, about contamination of the non-GM food supply, about effects of GMOs on the environment and nature, and about the consolidation of control of the food supply in companies that make and sell GMOs.
^Büttner-Mainik, A., et al (2011): Production of biologically active recombinant human factor H in Physcomitrella. Plant Biotechnology Journal 9, 373–383. 
^Baur, A., R. Reski, G. Gorr (2005): Enhanced recovery of a secreted recombinant human growth factor using stabilizing additives and by co-expression of human serum albumin in the moss Physcomitrella patens. Plant Biotech. J. 3, 331–340 
^EPA Reregistration Eligibility Decision (RED) Bacillus thuringiensis "The potential risk to humans from dietary, non-dietary and occupational exposures of the delta-endotoxins and most of the cellular components of Bacillus thuringiensis are considered negligible." (p 34) "As described in the environmental assessment, section III(C), there should be no unreasonable adverse effects on nontarget organisms, or ground or surface water contamination concerns, from the delta-endotoxins and most of the cellular components of Bacillus thuringiensis when used according to currently approved label rates." (p 34
^Leader, Benjamin; Baca, Qentin J.; Golan, David E. (January 2008). "Protein therapeutics: a summary and pharmacological classification". Nature Reviews Drug Discovery. A guide to drug discovery 7 (1): 21–39. doi:10.1038/nrd2399. PMID18097458.Cite uses deprecated parameters (help) Leader 2008 — Fee required for access to full text.
^Walsh, Gary (April 2005). "Therapeutic insulins and their large-scale manufacture". Appl. Microbiol. Biotechnol.67 (2): 151–159. doi:10.1007/s00253-004-1809-x. PMID15580495.Cite uses deprecated parameters (help) Walsh 2005 — Fee required for access to full text.
^Bryant, Jackie; Baxter, Louise; Cave, Carolyn B.; Milne, Ruairidh; Bryant, Jackie (2007). "Recombinant growth hormone for idiopathic short stature in children and adolescents". In Bryant, Jackie. Cochrane Database Syst Rev (3): CD004440. doi:10.1002/14651858.CD004440.pub2. PMID17636758. Bryant 2007 — Fee required for access to full text.
^Baxter L, Bryant J, Cave CB, Milne R (2007). "Recombinant growth hormone for children and adolescents with Turner syndrome". In Bryant, Jackie. Cochrane Database Syst Rev (1): CD003887. doi:10.1002/14651858.CD003887.pub2. PMID17253498.
^Panesar, Pamit et al (2010) "Enzymes in Food Processing: Fundamentals and Potential Applications", Chapter 10, I K International Publishing House, ISBN 978-93-80026-33-6
^Cabot, R. A.; Kühholzer, B.; Chan, A. W. S.; Lai, L.; Park, K. -W.; Chong, K. -Y.; Schatten, G.; Murphy, C. N.; Abeydeera, L. R.; Day, B. N.; Prather, R. S.; Prather, R. S. (2001). "Transgenic Pigs Produced Using in Vitro Matured Oocytes Infected with a Retroviral Vector". Animal Biotechnology12 (2): 205–214. doi:10.1081/ABIO-100108347. PMID11808636. edit
^Lai, L.; Park, K. W.; Cheong, H. T.; Kühholzer, B.; Samuel, M.; Bonk, A.; Im, G. S.; Rieke, A.; Day, B. N.; Murphy, C. N.; Carter, D. B.; Prather, R. S. (2002). "Transgenic pig expressing the enhanced green fluorescent protein produced by nuclear transfer using colchicine-treated fibroblasts as donor cells". Molecular Reproduction and Development62 (3): 300–306. doi:10.1002/mrd.10146. PMID12112592.edit
^Jabed, A.; Wagner, S.; McCracken, J.; Wells, D. N.; Laible, G. (2012). "Targeted microRNA expression in dairy cattle directs production of -lactoglobulin-free, high-casein milk". Proceedings of the National Academy of Sciences. doi:10.1073/pnas.1210057109.edit
^Rosenecker J, Huth S, Rudolph C (October 2006). "Gene therapy for cystic fibrosis lung disease: current status and future perspectives". Current Opinion in Molecular Therapeutics8 (5): 439–45. PMID17078386.Cite uses deprecated parameters (help)
^Persons DA, Nienhuis AW (July 2003). "Gene therapy for the hemoglobin disorders". Curr. Hematol. Rep.2 (4): 348–55. PMID12901333.Cite uses deprecated parameters (help)
^Lewitt, P. A.; Rezai, A. R.; Leehey, M. A.; Ojemann, S. G.; Flaherty, A. W.; Eskandar, E. N.; Kostyk, S. K.; Thomas, K.; Sarkar, A.; Siddiqui, M. S.; Tatter, S. B.; Schwalb, J. M.; Poston, K. L.; Henderson, J. M.; Kurlan, R. M.; Richard, I. H.; Van Meter, L.; Sapan, C. V.; During, M. J.; Kaplitt, M. G.; Feigin, A. (2011). "AAV2-GAD gene therapy for advanced Parkinson's disease: A double-blind, sham-surgery controlled, randomised trial". The Lancet Neurology10 (4): 309–319. doi:10.1016/S1474-4422(11)70039-4. PMID21419704.edit
^Wise De Valdez, M. R.; Nimmo, D.; Betz, J.; Gong, H. -F.; James, A. A.; Alphey, L.; Black, W. C. (2011). "Genetic elimination of dengue vector mosquitoes". Proceedings of the National Academy of Sciences108 (12): 4772. doi:10.1073/pnas.1019295108.edit
^Harris, A. F.; Nimmo, D.; McKemey, A. R.; Kelly, N.; Scaife, S.; Donnelly, C. A.; Beech, C.; Petrie, W. D.; Alphey, L. (2011). "Field performance of engineered male mosquitoes". Nature Biotechnology29 (11): 1034–1037. doi:10.1038/nbt.2019. PMID22037376.edit
^Hackett, P.B., Ekker, S.E. and Essner, J.J. (2004) Applications of transposable elements in fish for transgenesis and functional genomics. Fish Development and Genetics (Z. Gong and V. Korzh, eds.) World Scientific, Inc., Chapter 16, 532–580.
^Published PCT Application WO2000049150 "Chimeric Gene Constructs for Generation of Fluorescent Transgenic Ornamental Fish." National University of Singapore 
^Eric Hallerman Glofish, The First GM Animal Commercialized: Profits amid Controversy. June, 2004. Accessed September 3, 2012.
^Schuchat S. (2003) Why GloFish won't glow in California. San Francisco Chronicle.
^Shao Jun Du et al. (1992) Growth Enhancement in Transgenic Atlantic Salmon by the Use of an "All Fish" Chimeric Growth Hormone Gene Construct. Nature Biotechnology 10, 176–181 
^Devlin RF et al (2001) Growth of domesticated transgenic fish. Nature 409, 781–782 
^Rahman MA et al. (2001) Growth and nutritional trials on transgenic Nile tilapia containing an exogenous fish growth hormone gene. Journal of Fish Biology 59(1):62–78 
^Carvan MJ et al (2000) Transgenic zebrafish as sentinels for aquatic pollution. Ann N Y Acad Sci. 2000;919:133–47 
^Nebert DW et al (2002) Use of Reporter Genes and Vertebrate DNA Motifs in Transgenic Zebrafish as Sentinels for Assessing Aquatic Pollution. Environmental Health Perspectives 110(1):A15 | January 2002 
^Mattingly CJ et al (2001) Green fluorescent protein (GFP) as a marker of aryl hydrocarbon receptor (AhR) function in developing zebrafish (Danio rerio). Environ Health Perspect. 2001 Aug;109(8):845–9 
^Gaskell, G.; Bauer, M. W.; Durant, J.; Allum, N. C. (1999). "Worlds Apart? The Reception of Genetically Modified Foods in Europe and the U.S". Science285 (5426): 384–387. doi:10.1126/science.285.5426.384. PMID10411496.edit
^Wesseler, J. and N. Kalaitzandonakes (2011): Present and Future EU GMO policy. In Arie Oskam, Gerrit Meesters and Huib Silvis (eds.), EU Policy for Agriculture, Food and Rural Areas. Second Edition, pp. 23–323 – 23-332. Wageningen: Wageningen Academic Publishers
^Beckmann, V., C. Soregaroli, J. Wesseler (2011): Coexistence of genetically modified (GM) and non-modified (non GM) crops: Are the two main property rights regimes equivalent with respect to the coexistence value? In "Genetically modified food and global welfare" edited by Colin Carter, GianCarlo Moschini and Ian Sheldon, pp 201–224. Volume 10 in Frontiers of Economics and Globalization Series. Bingley, UK: Emerald Group Publishing
^A decade of EU-funded GMO research (2001–2010) (PDF). Directorate-General for Research and Innovation. Biotechnologies, Agriculture, Food. European Union. 2010. doi:10.2777/97784. ISBN978-92-79-16344-9. ""The main conclusion to be drawn from the efforts of more than 130 research projects, covering a period of more than 25 years of research, and involving more than 500 independent research groups, is that biotechnology, and in particular GMOs, are not per se more risky than e.g. conventional plant breeding technologies." (p. 16)"
^United States Institute of Medicine and National Research Council (2004). Safety of Genetically Engineered Foods: Approaches to Assessing Unintended Health Effects. National Academies Press. Free full-text. National Academies Press. pp R9-10: "In contrast to adverse health effects that have been associated with some traditional food production methods, similar serious health effects have not been identified as a result of genetic engineering techniques used in food production. This may be because developers of bioengineered organisms perform extensive compositional analyses to determine that each phenotype is desirable and to ensure that unintended changes have not occurred in key components of food."